New antibody drug aims to regrow hair – first human trial underway
NCT ID NCT07317544
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether ABS-201, an antibody that blocks a hormone receptor, is safe for treating hair loss. It starts with healthy volunteers and then includes people with male or female pattern baldness. Participants receive either the drug or a placebo and are monitored for about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABS-201 (a monoclonal antibody targeting the prolactin receptor)
What this could lead to
If safe and effective, ABS-201 could offer a new treatment option for hair loss by targeting a different biological pathway than current therapies.
What could go wrong
This is an early-phase trial focused on safety, not effectiveness. The drug may cause side effects or fail to improve hair growth. Results may not apply to all types of hair loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA (AGA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Momentum Darlinghurst
RECRUITINGSydney, New South Wales, 2010, Australia
Contact
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact
-
Nucleus Network Brisbane
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-••••
Contact
-
Sinclair Dermatology
RECRUITINGMelbourne, Victoria, 3002, Australia
Contact